Revolution Medicines Slides After Q4 Results RVMD fell ~12% on Mar 29, 2026 after Q4 commentary; cash of ~$650M as of Dec 31, 2025 implies runway into mid-2027, making H2 2026 and Q1 2027 readouts critical.

Revolution Medicines Slides After Q4 Results: RVMD fell ~12% on Mar 29, 2026 after Q4 commentary; cash of ~$650M as of Dec 31, 2025 implies runway into mid-2027, making H2 2026 and Q1 2027 readouts critical. 👈 Read full analysis #RevolutionMedicines #RVMD #Q4Results #StockMarket #Pharmaceuticals

Revolution Medicines Exec Sells $3.5m in Stock Revolution Medicines executive sold $3.5m in stock; SEC Form 4 filed Mar 26, 2026 and reported Mar 27, 2026 (Investing.com). Fazen Capital flags a 12% YoY rise in biotech insider monetizations in Q1 2026.

Revolution Medicines Exec Sells $3.5m in Stock: Revolution Medicines executive sold $3.5m in stock; SEC Form 4 filed Mar 26, 2026 and reported Mar 27, 2026 (Investing.com). Fazen Capital flags a 12% YoY rise… 👈 Read full analysis #RevolutionMedicines #Biotech #InsiderTrading #StockMarket #Investment

Takeda signs $1.7bn AI alliance with Iambic Iambic bags another pharma partner, Takeda, which plans to use its AI platform to find drugs for cancer, gastrointestinal, and inflammatory disorders

#Takeda #AIalliance #AI #IambicTherapeutics #drugdiscovery #inflammatorydiseases #oncology #NeuralPLexer #smallmoleculetherapeutics #RevolutionMedicines #neurology #Lundbeck #NablaBio #Arzeda #nference #CytoReason #AIStructuralBiology #AISBconsortium #OpenFoldstructure
zurl.co/wMIRf

MSD said to have pulled back from Revolution Meds deal Negotiations between MSD and Revolution Medicines over a possible $30bn takeover of Revolution Medicines have reportedly collapsed.

Negotiations between #MSD and #RevolutionMedicines over a possible takeover – estimated to have been potentially worth up to $30 billion – have reportedly ended without agreement.

Report says MSD is in talks to buy Revolution Meds MSD is rumoured to be in talks to buy Revolution Medicines and its KRAS inhibitor pipeline in a deal that could be worth up to $32 billion.

Could there be a third #bigpharma #acquisition this week? #MSD is rumoured to be in talks to buy #RevolutionMedicines in a deal that could be worth up to $32 billion.

pharmaphorum.com/news/report-...